Acute Kidney Injury Impacts On Hypokalemia Associated With Yokukansan Preparation: A Retrospective Observational Study
Feb 29, 2024
The time course of acute kidney injury and hypokalemia remains unelucidated. We investigated whether altered renal function impacts hypokalemia and clinical predictors for acute kidney injury in patients who used Yokukansan preparation. We performed a secondary analysis of retrospective observational cohort data from adult patients who started Yokukansan preparation. The study was conducted from June 2015 to May 2019 at Tokyo Women's Medical University, Medical Center East. The effect of acute kidney injury (>1.5-fold increase from baseline serum creatinine level) or renal function recovery on hypokalemia (serum potassium level <3.0 mEq/L) was investigated. The clinical predictors for acute kidney injury were determined using a multivariate Cox proportional hazard analysis. Out of 258 patients, 12 patients had both outcomes and all but one patient experienced in the order of acute kidney injury and hypokalemia. Excluding one patient, hypokalemia occurred in 11/34 (32%) patients after acute kidney injury and 27/223 (12%) patients without acute kidney injury (p= 0.005). Hypokalemia occurred in 9/25 (36%) of acute kidney injury with recovery, 2/9 (22%) of acute kidney injury without recovery, and 27/223 (12%) of no acute kidney injury (p= 0.014). Patients with acute kidney injury showed a late onset of hypokalemia compared with those without acute kidney injury (p= 0.001). In 258 patients, multivariate Cox proportional hazard analysis showed that high systolic blood pressure and mean arterial pressure increased the risk of acute kidney injury. Clinicians should remember that hypokalemia develops after acute kidney injury while Yokukansan preparation treatment.
Keywords acute kidney injury; blood pressure; hypokalemia; Yokukansan; Yokukansankachimpihange
CLICK HERE TO GET NATURAL ORGANIC CISTANCHE EXTRACT WITH 25% ECHINACOSIDE AND 9% ACTEOSIDE FOR ACUTE KIDNEY INJURY
Supportive Service Of Wecistanche-The largest cistanche exporter in the China:
Email:wallence.suen@wecistanche.com
Whatsapp/Tel:+86 15292862950
Shop For More Specifications Details:
https://www.xjcistanche.com/cistanche-shop
INTRODUCTION
Acute kidney injury (AKI) is associated with substantial morbidity and mortality in various populations.1–3) AKI pathogenesis is categorized as prerenal, renal, and postrenal.4,5) A thorough understanding of AKI etiology (e.g., septic shock, acute heart failure, electrolyte disorders, and medications) is essential to determine a therapeutic strategy.6)
Clinicians strongly invested in AKI treatment to discharge patients earlier and improve the late consequences of AKI. The introduction of intensive treatment for AKI could serve to increase renal potassium excretion, thereby driving the normalization of the serum potassium level because of the renal recovery process and the management of hyperkalemia.7) Thus, the recovery of renal function is a potential risk of hypokalemia. Conversely, hypokalemia itself was associated with the deterioration risk of renal function and all-cause mortality.8,9) There is a lack of information on the chronological order of the clinical events of AKI and hypokalemia. Yokukansan and Yokukansankachimpihange (both Tsumura Co., Tokyo, Japan), which include an equivalent amount of Glycyrrhiza. Yokukansan contains seven crude components (Atractylodes lancea rhizome, Poria sclerotium, Cnidium sp. rhizome, Uncaria sp. hook, Angelicae radix, Bupleuri radix, and Glycyrrhiza sp.). Yokukansankachimpihange contains Citrus unshiu peel and Pinellia sp. tuber in addition to Yokukansan. Glycyrrhetinic acid, the active metabolite of Yokukansan preparation (Yokukansan and Yokukansankachimpihange), inhibits 11β-hydroxysteroid dehydrogenase type 2, resulting in hypokalemia.10) Elderly patients often have a high risk of hypokalemia associated with Yokukansan preparation and AKI in clinical settings.11–13) Additionally, Yokukansan preparation induces pseudo-aldosteronism (hypokalemia and hypertension) and hypertension could be a potential predictor for AKI.14,15) Yokukansan preparation is often used in the older population to suppress the symptoms such as those of Alzheimer's disease by blocking the activity of the glutamate nervous system and stimulating serotonin 5-HT1A receptor.16,17) Therefore, we selected Yokukansan preparation as an ideal proven drug to address the clinical question regarding the time–-courses of AKI and hypokalemia.
This study aimed to identify the timeline of the development/ recovery of AKI and hypokalemia, the relationship between the development/recovery of AKI and hypokalemia, and clinical predictors for AKI.
MATERIALS AND METHODS
Study Design and Patient Eligibility
We further analyzed a previously described single-center retrospective observational cohort dataset collected between June 2015 and May 2019 at Tokyo Women's Medical University, Medical Center East (a 450-bed university hospital in Tokyo, Japan).13) The study population included inpatients and outpatients aged >20 years who started Yokukansan preparation between June 2015 and May 2019 and monitored their serum potassium levels during the treatment. The exclusion criteria included a baseline serum potassium level of <3.0 mEq/L, no multiple data for serum creatinine level, and baseline estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m2. This study was conducted in compliance with the Declaration of Helsinki and approved by the Institutional Review Board at Tokyo Women's Medical University (#5199).
Data Collection
The patient's electronic medical records were reviewed to collect data for demographic characteristics (sex, age, height, body weight, and body mass index), primary diagnosis (delirium, dementia, and other psychological illnesses), clinical laboratory data (serum albumin, blood urea nitrogen, serum creatinine, serum sodium, serum potassium, and serum chloride), vital signs (systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate), details of the Yokukansan preparation (dose and follow-up period), and medications of interest (benzodiazepine, ramelteon, suvorexant, cholinesterase inhibitors (donepezil, rivastigmine, and galantamine), N-methyl-D-aspartate antagonist (memantine), typical or atypical antipsychotics, oral corticosteroids, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, loop diuretics, thiazide diuretics, and potassium-sparing diuretics). We calculated the ratio of blood urea nitrogen to serum creatinine to assess the volume status.18) A prediction equation, including sex, age, and serum creatinine level, was used to determine the eGFR.19) Because we could not obtain blood gas data from the electronic medical records, we considered the gap between serum sodium and serum chloride as an alternative marker for the acid–base disturbance.20) We calculated mean arterial pressure (MAP) using the following equation.
Outcome We assessed two study outcomes during the Yokukansan preparation treatment: AKI and hypokalemia (serum potassium level <3.0 mEq/L). Because data on urine volume were unavailable, we assessed AKI based on Kidney Disease Improving Global Outcomes (KDIGO) criteria, using the definition of >1.5 times increase from the baseline serum creatinine level.21) There are concerns that the KDIGO criteria of a fixed increase of serum creatinine gives a false-positive result.22) Additionally, KDIGO timing criteria (48 h or 7 d) were primarily designed for intensive care settings.21)
Statistical Analysis Normally distributed data were reported as mean ± standard deviations and compared using Student's t-test, whereas non-normally distributed data were reported as medians and interquartile ranges (IQR) and compared using Mann–Whitney's U-test. Categorical data were presented as numbers and percentages, and heterogeneity was assessed using the chi-square test.
Time-to-event outcomes (AKI or hypokalemia associated with Yokukansan preparation) were analyzed based on Kaplan–Meier curves. The follow-up period was defined as the time from the introduction of Yokukansan preparation to the discontinuation of Yokukansan preparation or the development of outcome (AKI or hypokalemia). We compared the median onset and the incidence of hypokalemia between patients with and without AKI. Because we considered increased potassium excretion as evidence of renal function recovery, we further examined the development of hypokalemia according to AKI recovery. The recovery of renal function was defined as no less than a 1.0-fold decrease from baseline serum creatinine level within 1 week after AKI.23) We corrected the p-value by Bonferroni's correction. The corrected p values were set at 0.025 (0.05 divided by 2) assuming that two intergroup analyses were conducted. The clinical features of interest in patients with AKI and hypoxialamia were summarized. Furthermore, Kaplan–Meier curves analyzed the cumulative incidence of hypokalemia stratified by the AKI above mentioned. This comparison was used by the log-rank test. The index dates were the start of Yokukansan preparation for patients without AKI and the development of AKI for patients with AKI. We preliminary investigated clinical predictors for AKI using a multivariate Cox proportional hazard analysis. We assumed that approximately 12% of the older population developed AKI.24,25) Thus, our study required at least 250 patients to identify three independent variables in the final model if we assumed that 10 patients were required to detect one independent variable. The dependent variable was AKI development during the Yokukansan preparation treatment. The independent variables were demographic characteristics, primary diagnosis, clinical laboratory data, vital signs, the Yokukansan preparation dose, and medications of interest. eGFR was categorized as a binary variable (< 60 or ≥ 60 mL/min/1.73 m2 ) because this cut-off value was used for diagnosing chronic kidney disease.26) The daily dose of the Yokukansan preparation was categorized as ≥7.5 or <7.5 g because a daily dose of 7.5 g of Yokukansan preparation has been used in clinical trials.27) We prescreened potential independent variables using univariate Cox proportional hazard analyses, and all independent variables with a p-value <0.10 were further evaluated in the multivariate Cox proportional hazard analysis. We confirmed each independent variable for multicollinearity. Additionally, we constructed three final models using three blood pressure components (SBP, DBP, and MAP), because the effect of each blood pressure on renal function differed.28) We used a stepwise backward selection method to construct three final models according to the Akaike information criterion. The robustness of the final models was confirmed using a stepwise forward selection method. Three final models were used to determine the hazard ratio (HR) and 95% confidence interval (95% CI). We attempted to examine the interactions of independent variables by introducing a cross-product term of respective independent variables into each final model as needed.
All statistical analyses were two-sided and performed using JMP® Pro 14 (SAS Institute Inc., Cary, NC, U.S.A.). A p-value <0.05 was considered statistically significant unless otherwise mentioned. Figures were prepared using GraphPad Prism ver. 8.00 (GraphPad Software, San Diego, CA, U.S.A.).
RESULTS
Study Population
A flow chart of the eligible populations is depicted in Fig. 1. We identified 678 patients at Tokyo Women's Medical University, Medical Center East, who were >20 years old and who had started Yokukansan preparation between June 2015 and May 2019. Of them, we excluded 13 with a baseline serum potassium level <3.0 mEq/L, 307 with no multiple data for serum creatinine, and 100 with a baseline eGFR <30 mL/min/1.73 m2. The remaining 258 patients were included in the main analysis.
Table 1 shows the baseline clinical characteristics of the study cohort. Approximately 60% of patients were male. The median age was younger in the AKI group than the no AKI Fig. 1. The Flow Chart of Eligible Populations We identified 678 patients between June 2015 and May 2019 at Tokyo Women's Medical University, Medical Center East, who were >20 years old and used Yokukansan preparation (Yokukansan and Yokukansankachimpihange). We excluded 420 patients because of baseline serum potassium level <3.0 mEq/L, no multiple data for serum creatinine level, and baseline estimated glomerular filtration rate <30 mL/min/1.73 m2 (13, 307, and 100 patients, respectively). The final study cohort included 258 patients. Of them, 35 (14%) developed acute kidney injury, and 223 (86%) of patients did not. Hypokalemia developed in 12 (34%) patients in the acute kidney injury group and 27 (12%) patients in the no acute kidney injury group. Among 12 patients with acute kidney injury and hypokalemia, 11 (92%) patients experienced subsequent hypokalemia after acute kidney injury. N, number; K, potassium; Cr, creatinine; eGFR, estimated glomerular filtration rate, AKI; acute kidney injury group (75 [68–81] vs. 80 [73–85] years old, p< 0.01). The majority of patients had hypoalbuminemia (mean serum albumin <3.0 g/dL), and 83% of the patients in both groups received a daily dose of ≥ 7.5 g Yokukansan preparation.
Trends of AKI and AKI Recovery on Hypokalemia
The Kaplan–Meier curve revealed that the cumulative incidence for AKI was 35 of 258 (14%) patients with a median follow-up period of 10 (IQR: 5–26) days (Fig. 2). The Kaplan– Meier curve for the cumulative incidence of hypokalemia is depicted in Supplementary Fig. 1. There were 12 of 35 (34%) patients with both AKI and hypokalemia. The median onset of hypokalemia was 35 (IQR: 18–146) days in patients with AKI, which was significantly longer than in patients without AKI (18 d, IQR:10–36) (p= 0.001). Table 2 shows the clinical features of interest in patients with both AKI and hypokalemia. There were 11 of 12 (92%) patients who experienced subsequent hypokalemia after AKI. The median period from AKI to the development of hypokalemia was 30 (IQR: 13–47) days.
Excluding one patient who developed hypokalemia before AKI, the clinical courses of AKI and hypokalemia associated with Yokukansan preparation are summarized in Table 3. The risk of hypokalemia was higher in 11 of 34 (32%) patients with AKI than in 27 of 223 (12%) patients without AKI (p= 0.005). Of the 34 patients who experienced AKI, 25 (74%) recovered. Hypokalemia was observed in 9 of 25 (36%) patients with AKI recovery, 2 of 9 (22%) patients without AKI recovery, and 27 of 223 (12%) patients without AKI (p= 0.014). The median onset of hypokalemia in patients with and without AKI recovery was significantly longer than that in patients without AKI (56 [23–149] vs. 25 [10–615] vs. 18 [10–36], p< 0.001). However, the Kaplan–Meier curve revealed no difference in the cumulative incidence of hypokalemia (Supplementary Fig. 2, log-rank test, p= 0.303). Clinical Predictors of AKI Focusing on included 258 patients, univariate Cox proportional hazard analyses identified SBP, DBP, MAP, oral corticosteroids, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, potassium-sparing diuretics, and a daily dose of Yokukansan preparation of ≥ 7.5 g as potential independent variables for AKI. There was no multicollinearity except for the blood pressure component. A stepwise backward selection method determined three final models (Table 4), all of which remained unchanged regardless of a stepwise forward selection method. The final model demonstrated that SBP was the clinical predictor for AKI during Yokukansan preparation treatment (Model 1, HR = 1.007, 95% CI; 1.000–1.013, p= 0.036). However, DBP was an insignificant clinical predictor for AKI (Model 2, HR = 1.008, 95% CI; 0.999–1.018, p= 0.093). Conversely, MAP was a significant predictor for AKI (Model 3, HR = 1.010, 95% CI; 1.001–1.019, p= 0.035). A daily dose of ≥7.5 g/d Yokukansan preparation was significantly associated with AKI in Model 1 (HR = 1.520, 95% CI; 1.026–2.325, p= 0.036). As shown in Table 1, the limited number of patients who used Yokukansan preparation <7.5 g/d might contribute to an alpha error (false-positive). We did not perform further analysis of the interaction between blood pressure components and the daily dose of Yokukansan preparation.
